|
Nov 20
|
Spotlight On 3 US Penny Stocks With At Least $60M Market Cap
|
|
Nov 14
|
XFOR: Positive Results for Phase 2 Trial of Mavorixafor in Chronic Neutropenia…
|
|
Nov 14
|
X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference
|
|
Nov 14
|
X4 Pharmaceuticals Inc (XFOR) Q3 2024 Earnings Call Highlights: Strategic Engagement and ...
|
|
Aug 28
|
X4 Pharmaceuticals to Participate in Upcoming September Investor Conferences
|
|
Jul 30
|
X4 Pharmaceuticals to Report Second Quarter 2024 Financial Results and Host a Conference Call and Webcast on August 8, 2024
|
|
Jul 8
|
XFOR: Positive Interim Data from Ongoing Phase 2 Trial of Mavorixafor in Chronic Neutropenia Patients…
|
|
Jun 27
|
X4 Pharmaceuticals Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) and Initiation of Pivotal Phase 3 CN Trial
|
|
May 13
|
X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
|
|
May 9
|
X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility
|
|
May 8
|
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q1 2024 Earnings Call Transcript
|
|
May 8
|
XFOR: Data from Phase 2 CN Trial Expected in June 2024…
|
|
May 8
|
X4 Pharmaceuticals Inc (XFOR) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights ...
|
|
May 7
|
X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
|
|
Apr 30
|
X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024
|
|
Apr 30
|
XFOR: XOLREMDI™ Approved by FDA…
|
|
Apr 29
|
UPDATE 1-US FDA approves X4 Pharmaceuticals' therapy for immunodeficiency disease
|
|
Apr 29
|
X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome
|
|
Apr 11
|
X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) market cap decline of US$42m may not have as much of an impact on institutional owners after a year of 7.0% returns
|
|
Apr 2
|
XFOR: PDUFA Date of April 30, 2024 for Mavorixafor for WHIM Syndrome…
|